Clinical profile and prognosis of brugada syndrome SCN5A variant carriers with negative sodium channel blocker challenge
Authors:
- Elodie SurgetESElodie Surget
- Gael ClericiGCGael Clerici
- Frédéric SacherFSFrédéric Sacher
- Raphael MartinsRMRaphael Martins
- Philippe MauryPMPhilippe Maury
- Isabelle DenjoyIDIsabelle Denjoy
- Aurélie TholletATAurélie Thollet
- Julien BarcJBJulien Barc
- Jean Jacques SchottJSJean Jacques Schott
- Richard RedonRRRichard Redon
- Jean Baptiste GourraudJGJean Baptiste Gourraud
Open Access
- 10 March 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (3)
Abstract
Loss-of-function (LOF) variants in SCN5A are associated with Brugada syndrome (BrS), progressive conduction slowing, and other arrhythmias. While the prognosis of SCN5A carriers with a positive sodium channel blocker challenge (SCBC) is established, data on those with negative SCBC are limited. To assess the clinical presentation and prognosis of SCN5A variant carriers with negative SCBC, and compare them to relatives with positive SCBC. We retrospectively included patients from five university hospitals (2000–2024) carrying a pathogenic or likely pathogenic SCN5A variant and negative SCBC. Relatives with the same variant and positive SCBC were also analysed. Patients with spontaneous type 1 ECG, gain-of-function variants, double variants, or ACMG class 1–3 variants were excluded. Clinical, ECG, genetic, and follow-up data were collected. Conduction slowing was evaluated using the PR interval and QRS duration. The cohort included 162 patients from 43 families (median age 37 ± 19 years, 46% male), of whom 69 (43%) had negative SCBC. Among these 69 patients, 25 (36%) had baseline intraventricular conduction defects, and 19 (28%) had first-degree AV block. After a median follow-up of 75 [40–168] months, 52% of patients developed progressive conduction slowing. Negative SCBC patients had fewer conduction defects (36% vs. 70%, p = 0.002) and ICD implantations (1% vs. 23%, P < 0.001). Non-missense variants were associated with more conduction slowing (71% vs. 42%, P = 0.04). This multicentre study provides the largest analysis of SCN5A carriers with negative SCBC, showing excellent arrhythmic prognosis despite frequent progressive conduction slowing.Keywords
Funding Information
- European Innovation Council of the European Union
This publication has 32 references indexed in Scilit:
- Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challengesEP Europace, 2009
- Significance of QRS prolongation during diagnostic ajmaline test in patients with suspected Brugada syndromeHeart Rhythm, 2009
- Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathiesHeart Rhythm, 2009
- Clinical and Electrophysiological Characteristics of Brugada Syndrome Caused by a Missense Mutation in the S5‐Pore Site of SCN5AJournal of Cardiovascular Electrophysiology, 2005
- Brugada Syndrome: Report of the Second Consensus ConferenceCirculation, 2005
- Inherited Sodium Channelopathies A Continuum of Channel DysfunctionTrends in Cardiovascular Medicine, 2004
- Compound Heterozygosity for Mutations (W156X and R225W) in SCN5A Associated With Severe Cardiac Conduction Disturbances and Degenerative Changes in the Conduction SystemCirculation Research, 2003
- Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenègre diseaseJACC, 2003
- A sodium-channel mutation causes isolated cardiac conduction diseaseNature, 2001
- Cardiac conduction defects associate with mutations in SCN5ANature Genetics, 1999